Your current web browser is outdated. For best viewing experience, please consider upgrading to the latest version.

Donation - Other Level

Please use the quantity box to donate any amount you wish. Sign Up to Donate

Contact

Send a question or comment using the form below. This message may be routed through support staff.

Email Article

Password Reset Request

Register


Add a topic or expert to your feed.

Following

Follow Experts & Topics

Stay on top of our work by selecting topics and experts of interest.

Experts
Topics
Project
On The Ground

RSVP

Lecture

FDA Regulation In An Era of Precision Medicine

Scott Gottlieb, MD Commissioner, U.S. Food and Drug Administration
Thu, Dec 14, 2017 New York City

Thank you for your RSVP.

ERROR
Main Error Mesage Here
More detailed message would go here to provide context for the user and how to proceed
ERROR
Main Error Mesage Here
More detailed message would go here to provide context for the user and how to proceed

Manhattan Institute

search
Close Nav

FDA Regulation In An Era of Precision Medicine

SEE ALL EVENTS
Lecture

FDA Regulation In An Era of Precision Medicine

Scott Gottlieb, MD Commissioner, U.S. Food and Drug Administration
New York City 06:00pm—07:30pm
Thursday December 14
Thursday December 14 2017
PAST EVENT Thursday December 14 2017

On December 14, the Manhattan Institute was joined by FDA Commissioner Scott Gottlieb for a discussion on drug development and regulation reform at the U.S. Food and Drug Administration. Video will be available shortly!

Medical innovation is changing fast, from its traditional focus on mass-market drugs to the current emphasis on precision medicines. Take Kymriah, recently approved by the Food and Drug Administration. The wonder drug uses patients' genetically modified immune cells to hunt down and kill their cancer cells—a life-saving treatment for children whose leukemia has proved unresponsive to other therapies.

But breakthrough innovations may also pose long-term risks that are poorly understood. They can also raise prices, especially in the short-run, for a U.S. health-care system plagued by high costs and uneven outcomes.

How can the FDA best shield the public from dangerous drugs while spurring access to promising new treatments? How can regulators help lower the cost and time needed to develop life-saving—and life-improving—therapies? Please join FDA Commissioner Scott Gottlieb, as he discusses his vision for the agency.

Scott Gottlieb is the commissioner of the U.S. Food and Drug Administration. Previously, he served as FDA deputy commissioner; as a senior advisor at the FDA and at the Centers for Medicare and Medicaid Services; as a fellow at the American Enterprise Institute; and as a professor at the New York University School of Medicine, where he also practiced medicine. He holds a B.A. from Wesleyan University and an M.D. from the Mount Sinai School of Medicine.

MEDIA CONTACT

212-599-7000
communications@manhattan-institute.org

TOPICS
Health PolicyFDA Reform
Saved!
Close